Filtered By:
Specialty: Pharmaceuticals
Condition: Pain
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Zynex Appoints Director of Business Development
LONE TREE, CO--(Healthcare Sales & Marketing Network) - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological di... Devices, PersonnelZynex, NeuroDiagnostics
Source: HSMN NewsFeed - June 25, 2014 Category: Pharmaceuticals Source Type: news
FDA Strengthens Warnings on Class of Painkillers
The FDA strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin IB and Aleve.
Source: WSJ.com: Health - July 10, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news
Zynex Hires Vice President of Operations
LONE TREE, Colo., June 6, 2016 -- (Healthcare Sales & Marketing Network) -- Zynex (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodi... Devices, PersonnelZynex, electrotherapy, NeuroMove
Source: HSMN NewsFeed - June 6, 2016 Category: Pharmaceuticals Source Type: news
Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide, nearly44 million people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news
Getting Social in the Real World
Although it would be facetious to say that social media has reached a tipping point into ubiquity, it is only relatively recently that it has been used by pharma to collect and analyze patient data. This use of social media may only be in its infancy but as a quick and inexpensive way to gather large-scale, real-world data it is growing rapidly.Technology always outstrips the glacial pace that industry moves at, but this ‘sudden’ move creates a sharp learning curve for many pharma companies. Issues around regulation and resources will hinder some, while others will fail to see the value of ‘social health’.Popular s...
Source: EyeForPharma - March 6, 2017 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news
Neurological diseases cost the US nearly $800 billion per year
A new paper published in the Annals of Neurology reports the most common neurological diseases pose a serious annual financial burden for the nation. The report notes that the current estimated annual cost to American society of just nine of the most common neurological diseases is staggering, totaling $789 billion in 2014 dollars. These conditions include Alzheimer's disease and other dementias, low back pain, stroke, traumatic brain injury, migraine, epilepsy, multiple sclerosis, spinal cord injury, and Parkinson's disease.
Source: World Pharma News - March 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Zynex Hires Chief Financial Officer
LONE TREE, Colo., June 9, 2017 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Neurology, Personnel Zynex, electrotherapy
Source: HSMN NewsFeed - June 9, 2017 Category: Pharmaceuticals Source Type: news
Zynex introduces the NeuroMove(TM) Device to its expanding sales force
LONE TREE, Colo., Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Product Launch Zynex, electrotherapy, NeuroMove
Source: HSMN NewsFeed - February 1, 2018 Category: Pharmaceuticals Source Type: news
Do you know the warning signs of peripheral artery disease?
Peripheral arterial disease (PAD) is a general term usually referring to arterial blockage of the lower extremities and most commonly a result of the development of atherosclerotic plaque. It is generally found in patients over the age of 60 years, more often in men than women, and is frequently associated with other areas of arterial disease, including that of heart disease and stroke.
PAD has a variety of manifestations ranging from no symptoms at all to symptoms of leg pain in the muscles…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2019 Category: Pharmaceuticals Authors: Dr. Brooks Whitney Source Type: news
Zynex names new Vice President of Sales and Marketing
ENGLEWOOD, Colo., Feb. 28, 2019 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabili... Devices, Neurology, Personnel Zynex, electrotherapy
Source: HSMN NewsFeed - February 28, 2019 Category: Pharmaceuticals Source Type: news
Zynex Expands Executive Team, Appoints Joseph Papandrea Chief Operating Officer
ENGLEWOOD, Colo., July 22, 2019 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabili... Devices, Personnel Zynex, NeuroMove
Source: HSMN NewsFeed - July 22, 2019 Category: Pharmaceuticals Source Type: news
Pelosi ’s radical plan would leave patients with sickle cell disease behind
Sickle cell disease (SCD) is the most commonly inherited genetic blood disorder, affecting nearly 100,000 children and adults in the United States. Three million Americans carry the sickle cell trait and it is nearly25 times more common in people of African American descent. The disorder, which can cause irregularly shaped blood cells to get stuck in narrow vessels, inflicts substantial pain on patients. The resulting reduced oxygen flow creates life-threatening complications such as difficulty breathing, chest pains, blood clots and stroke.
Source: The Catalyst - November 14, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Rare Diseases Pelosi Plan Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
